Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes.
Abdur Rehman KhalidFarooq AhmadMuhammad Ahrar Bin NaeemSmak AhmedMuhammad UmarHassan MehmoodMuhammad KashifShazib AliPublished in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2024)
Both drugs are generally safe for treating ACS patients with HBR at baseline, although a higher risk of MI was observed with the use of clopidogrel. Nevertheless, drug choice should factor in regional variations, patient-specific characteristics, cost, accessibility, and potential drug interactions.
Keyphrases
- acute coronary syndrome
- antiplatelet therapy
- percutaneous coronary intervention
- systematic review
- end stage renal disease
- st segment elevation myocardial infarction
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- chronic kidney disease
- st elevation myocardial infarction
- coronary artery disease
- prognostic factors
- atrial fibrillation
- randomized controlled trial
- climate change
- human health